Navigation Links
Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
Date:5/7/2008

U.S. Patent Encompassing Tobramycin Inhalation Powder and Other

Aminoglycoside Antibiotics Issued to Nektar

SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Patent and Trademark Office has issued Patent No. 7,368,102, which covers compositions and methods for creating and delivering Tobramycin Inhalation Powder (TIP) and other aminoglycoside antibiotics delivered via Nektar's proprietary Dry Powder Inhaled Technology. This patent extends through the year 2022.

TIP is being co-developed by Nektar and Novartis and is currently in Phase 3 development for the prevention and treatment of Pseudomonas aeruginosa pneumonia. Cystic fibrosis patients are susceptible to chronic infection by P. aeruginosa, which is responsible for high rates of illness and death in this patient population. Nektar's Dry Powder Inhaled Technology has the capability to administer high local lung concentrations of TIP that may provide significant benefits to patients suffering from this debilitating disease.

"Issuance of this patent further demonstrates the power of Nektar's pulmonary technology platform, as well as our industry leadership in the emerging field of targeted anti-infective therapeutics," said Nektar President and Chief Executive officer, Howard W. Robin. "Nektar will continue to aggressively file patents to ensure that the company remains at the forefront of our fields."

About Cystic Fibrosis

Cystic fibrosis (CF) is a genetic disease. About 30,000 people in the United States and about 70,000 people worldwide have CF. Patients with CF have abnormal movement of salt in and out of the cells lining their lungs, which leads to secretion of thick, sticky mucus that supports bacteria growth. Pseudomonas aeruginosa is the most common bacterium causing lung infections in people with CF. By the age of 17, nearly 70 percent of people with CF have Pseudomonas aeruginosa in their lungs. Pseudomonas aeruginosa infections cause lung inflammation and -- through cycles of inflammation, obstruction and infection -- deterioration of lung function, at an estimated average rate of 1.4 percent to 4 percent per year. Treatment of CF lung disease is aimed at controlling infection, reducing lung obstruction and decreasing inflammation.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar applies its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of dry powder inhaled tobramycin, Nektar's intellectual property position on dry powder inhaled tobramycin and compositions of other aminoglycoside antibiotics, and Nektar's technology platforms and business. These forward-looking statements involve important risks and uncertainties, including but not limited to: (i) Nektar's actual revenue from inhaled tobramycin will depend on Novartis's sales of inhaled tobramycin, (ii) Nektar and its partners' efforts to develop product candidates based on its technology platforms is subject to numerous scientific, clinical and regulatory risks and the risk of failure is high and can unexpectedly occur at any stage, (iii) dry powder inhaled tobramycin is not yet an approved drug and therefore there are numerous risks and uncertainties related to completing clinical development and obtaining regulatory approval to market any drug candidate, and (iv) other of Nektar's patent applications may fail to issue; patents that have issued may not be enforceable; or unanticipated intellectual property licenses from third parties may be required in the future. Other important risks and uncertainties are detailed in the Nektar's reports and other filings with the Securities and Exchange Commission including its most recent Annual Report on Form 10-K. Actual results could differ materially from the forward-looking statements contained in this press release. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

Tim Warner (650) 283-4915 or twarner@nektar.com

Stephan Herrera (415) 488-7699 or sherrera@nektar.com

Jennifer Ruddock (650) 631-4954 or jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
2. West Concludes Agreement with Nektar
3. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
4. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
5. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
8. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, ... Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding the use of ... PathSensors deploys the CANARY® test platform for the detection of harmful pathogens, including ...
(Date:4/27/2016)... , ... April 27, 2016 , ... Global Stem ... GSCG Advisory Board. Ross is the founder of GSCG affiliate Kimera Labs in Miami. ... where he studied hematopoietic stem cell transplantation for hematologic disorders and the suppression of ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... LOS ANGELES, Calif. (PRWEB) , ... April 27, ... ... Los Angeles office of Lewis Roca Rothgerber Christie LLP as an associate in ... and prosecuting U.S. and international electrical, mechanical and electromechanical patent applications. He has ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
Breaking Biology News(10 mins):